Life Sciences News Archives

08/10/2011
Relievant Medsystems Receives FDA Approval to Begin Pivotal Study
08/09/2011
Second Genome Raises $5M Series A To Map Microbes
08/08/2011
Second Genome Announces Series A Financing
08/08/2011
Morgenthaler Welcomes Juan-Pablo Mas to Life Science Team
07/28/2011
Morgenthaler Appoints Juan-Pablo Mas as Senior Associate
07/01/2011
Hank Plain Wins Most Valuable BOD Award for Ardian & Acclarent
06/03/2011
Miramar Labs Whips Up $38.5M to Zap Sweat Glands
05/25/2011
Morgenthaler Launches DC to VC: HIT Startup Showcase
03/02/2011
The Foundry, a Model of Consistency for Incubators
02/08/2011
Miramar Labs Receives FDA Clearance
01/31/2011
The Masterminds of Ardian
01/13/2011
Medtronic Completes Acquisition of Ardian
01/12/2011
Device Makers Target High Blood Pressure
12/23/2010
Looking Back On A Very Good M&A Year
12/06/2010
Devices Target Drug Space
12/01/2010
With Ardian, Sadra Deals Show Appetite for Big, Early-Stage Acquisitions
11/24/2010
Medtronic Buys Ardian for $800M
11/23/2010
Morgenthaler’s Seed Stake in Ardian Pays Off
11/22/2010
Medtronic Acquires Ardian for $800 Million
11/17/2010
Ardian’s Device Zaps Kidney Nerves to Reduce Blood Pressure
11/16/2010
Ardian Corrals Out-of-Control High Blood Pressure With First-of-its-Kind Device
11/03/2010
Satiety’s TOGA Named Top 10 Medical Innovation by the Cleveland Clinic
10/06/2010
Pfizer Completed Acquisition of FoldRX
09/06/2010
Promedior Avoids Redundancy
07/30/2010
Calithera is latest bio venture for Molineaux
07/08/2010
Calithera Secures $40M Series A led by Morgenthaler
06/18/2010
OncoMed Scores Big Cancer Development Pact with Bayer
06/17/2010
OncoMed and Bayer Announce Strategic Alliance
06/03/2010
Ardian Receives 2010 EuroPCR Innovation Award
06/01/2010
SetPoint Medical Featured in Technology Review
05/21/2010
CBSA BioBreakfast Focuses on Two CO Success Stories
05/04/2010
Stemgent and Miltenyi Announce Strategic Partnership
03/19/2010
Elcelyx Therapeutics Gets $1.2M
03/16/2010
Promedior Closes $12M Series C Financing
02/03/2010
Nobel Laureate Thomas Cech Joins Morgenthaler
01/20/2010
Optiscan Announces Management and Board Changes
01/19/2010
GlobeImmune Announces $17.5M Series E Financing
12/02/2009
Trellis Getting $338M in RSV MedImmune Deal
11/30/2009
Ardian: Succeeding Where Drugs Fail
09/09/2009
Transcend Medical Announces Management and Board Changes
08/13/2009
Screening Could Lead to More Potent Cancer Drugs
08/04/2009
Health Overhaul Opens Opportunities
07/22/2009
Symphony Medical Changes Name to CardioPolymers, Inc.
07/15/2009
Morgenthaler Adds Jason Lettmann to its Life Science Team
07/08/2009
Spinal Device Co. Relievant Takes In $20M Series C
07/08/2009
Relievant Medsystems Announces Completion of $20M Financing
07/06/2009
Catalyst Announces Agreement with MedImmune to Develop Engineered Protease Therapeutics
06/30/2009
Catalyst and Wyeth Announce Worldwide Collaboration
06/22/2009
Transcend Medical Raises $35M Series B Round
06/10/2009
Bayhill Therapeutics Enters Exclusive, Worldwide Collaboration with Genentech for BHT-3021 in Type 1 Diabetes
06/10/2009
Bayhill Enters Exclusive, Worldwide Collaboration with Genentech
06/03/2009
Procedure hailed for major weight loss
05/15/2009
GlobeImmune and Celgene Corp. Announce Strategic Global Oncology Alliance
03/30/2009
Ardian Announces Advances in Treating Hypertension
03/24/2009
Stemgent, CellDesign Sign Co-Exclusive Marketing Agreement
03/23/2009
Ardian Completes $47M Financing
02/11/2009
Stemgent Signs License Agreement with TET Systems
01/21/2009
Tragara Announces an Exclusive Worldwide License Agreement
01/05/2009
OncoMed and Fluidigm Announce Strategic Collaboration
12/03/2008
Catalyst Raises $40M in Series C Financing
11/05/2008
OncoMed Raises Largest Private Biotech Round this Year
11/04/2008
OncoMed Completes Series B Financing
10/20/2008
Satiety, Weight-Loss Surgery with No Cutting Required
10/13/2008
Miramar Labs Names Darrell Zoromski as CEO
10/06/2008
IPC’s Singer honored as Physician Entrepreneur of the Year
09/22/2008
Vertiflex Strengthens its Executive Management Team
06/15/2008
OncoMed Leads the Wave of Cancer Stem Cell Research
06/09/2008
Robin Bellas on the Surge in Life Science Investing
04/07/2008
Hank Plain is Bullish on Drug-eluting Stents
04/01/2008
OncoMed Emerges as Commercial Leader in Cancer Stem Cell Therapies
03/31/2008
CardioMind Small Vessel Stent Enters Human Clinicals
03/03/2008
IPC’s IPO Enjoys Healthy Public Reception
02/08/2008
Promedior Aims Big in New Approach to Fibrosis
02/01/2008
Robin Bellas on the Outlook for Medical Device Investing
01/28/2008
IPC The Hospitalist Company Juices Up IPO Market
01/07/2008
ForSight Labs Announces Formation of its Third Company and Closing of $6M in Series A Funding
12/27/2007
Six Leaps of Innovation for 2008
12/10/2007
OncoMed and GlaxoSmithKline Form Alliance to Develop Cancer Stem Cell Antibody Therapeutics
11/27/2007
Robin Bellas on How Medical Device Investing Avoids Stock Market Storms
10/18/2007
QLT’s Acquisition of ForSight Newco II
10/09/2007
ForSight Labs Announces Acquisition of ForSight Newco II by QLT
10/07/2007
Robin Bellas On Why Medical Device Investing Is Taking Off
09/04/2007
Hank Plain Joins Morgenthaler as Partner
07/23/2007
Robin Bellas On The New Surge in Medical Device Investing
07/17/2007
Satiety Completes $30M Series D Financing
06/07/2007
Chris Christoffersen on Producing New Stem Cells
05/16/2007
Chris Christoffersen’s Winning Streak
05/11/2007
Bayhill Appoints Fred Kurland as Chief Financial Officer
04/10/2007
Spine Wave Secures $45M Series D Round
04/02/2007
ForSight Labs Announces New CEO Appointment and Funding of a Second Company
03/23/2007
Eisai Taking Over Morphotek; $325M For Antibody Foothold
03/22/2007
Morphotek Investors To See $350M From Sale To Eisai
03/15/2007
IPC-The Hospitalist Co. Mulls IPO Prospects
03/15/2007
Morgenthaler Invests in anti-cancer, Anti-inflammation Platform
03/14/2007
Tragara Announces Corporate Launch and Series A Financing
12/11/2006
Antibiotics—an investment worth making?
11/10/2006
Transcend Medical Announces New CEO and Series A Funding
10/27/2006
Cosmetic Laser Company to Sell 6M Shares
10/16/2006
Taking the Pulse of the Stent Market
10/02/2006
Amgen Takes Over Avidia: Deal Valued Up To $450M
10/02/2006
Amgen To Pay $290M For Avidia, Its First Portfolio Buy
09/26/2006
Amgen to acquire Mountain View biotech firm Avidia for up to $380 million
09/06/2006
Medical devices: Silicon Valley’s emerging glamour sector
09/05/2006
Morgenthaler Co-leads $7M Trellis Spin-off’s Funding
08/08/2006
The heart device company hopes to raise funds to pump into drug-eluting stents
07/13/2006
J&J Buys Ensure Medical
06/26/2006
Stem Cells: The Real Culprits in Cancer?
06/05/2006
Device Valuations Strong In 1Q Financings
05/15/2006
Skills, Jobs, Competitiveness and Innovation
04/23/2006
A quiet crisis
04/11/2006
Replidyne Named One of Fierce 15
02/22/2006
Catalyst Announces Appointment of Nassim Usman as CEO
02/22/2006
Catalyst Announces Appointment of Nassim Usman as CEO
02/09/2006
Catalyst Biosciences Eyes Clinic After $30M Series B
02/06/2006
Surviving as a Stent Startup
01/26/2006
Patent Reform in Congress Divides Venture Capital Industry
12/26/2005
Biotech Bets
12/09/2005
Robin Bellas Selected to Author Chapter for “Inside the Minds: Life Sciences Venture Capital”
10/31/2005
How to Improve Series-B Round Valuations
10/18/2005
Q3 Fund Raising Results
05/23/2005
Six Morgenthaler Portfolio Companies Win Top 100 Award
04/29/2005
Firms Say New Drug-Eluting Stents Still Needed
03/17/2005
Morgenthaler Opens Boston Office
02/04/2005
Threshold Pharmaceuticals Announces Initial Public Offering
03/23/2003
Filters for Preparing to Meet a Venture Capitalist

© Morgenthaler

Home | Information Technology | Life Sciences | Private Equity | Limited Partner Login | Jobs

Links to other Web sites found here are provided to assist you in locating information. Morgenthaler is not responsible for the content of the Web sites found at these links, or beyond, and does not attest to the accuracy, completeness or timeliness of the information they contain. In addition, we have highlighted a select number portfolio companies on a number of our Web pages, but encourage you to review our entire portfolio listed in our Portfolio tabs.